cancer-treatment

Documents about cancer-treatment

• Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas#195398ClinicalTrials.gov
• Early treatment interruption and nutritional status as predictors of mortality in <i>Mycobacterium avium</i> complex pulmonary disease#232900PLOS
• The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of GC or EGJC With PM#234442ClinicalTrials.gov
• The complete treatment and management of brain metastases in a patient with limited-stage small cell lung cancer under molecular residual disease (MRD) monitoring: a case report.#280986NCBI PubMed Central
• A Single-arm Clinical Trial Using Patient-derived Tumor Tissue Fragment Models for Drug Sensitivity Testing to Guide Treatment in Previously Treated Cancers#287544ClinicalTrials.gov
• The impact of facilitating patient involvement on decisional conflict among patients undergoing surgical treatment for lung cancer: the serial mediating roles of hope level and social support.#381071NCBI PubMed Central
• The Efficacy and Safety of First-line Treatment Combined With Immunotherapy for Advanced Hepatocellular Carcinoma: a Single Center, Real-world Study#426782ClinicalTrials.gov
• Variation in uptake and dose reduction of CDK4/6 inhibitors for the treatment of breast cancer in England, 2019–2024: a descriptive observational study using OpenPrescribing Hospitals#475658Europe PMC
• Radiomic prediction of early progression at 2 years post-treatment in patients with resectable rectal cancer based on rectal tumor and mesentery characteristics: a two-center study.#666101NCBI PubMed Central
• Machine learning-based prediction and external validation of treatment-related myelosuppression in patients with non-small cell lung cancer receiving PD-1 inhibitors plus platinum-doublet chemotherapy.#685575NCBI PubMed Central
• Lymphocyte Depletion and Change in Lymphocyte Functionality#804372ClinicalTrials.gov
• Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers#414489ClinicalTrials.gov
• Rectal cancer - French intergroup clinical practice guidelines for diagnosis, treatment, and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF, SFR, and GRECCAR)#26295HAL (France)
• Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor#148749ClinicalTrials.gov
• NOXA/MCL-1 axis determines cell-death decision between apoptosis and a GSDME-dependent cell death associated with production of inflammatory cytokines upon treatment of breast cancer cells with antimitotics#284387HAL (France)
• Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer#366587ClinicalTrials.gov
• Diagnosis and treatment coverage among hepatitis C infections in Denmark, 2022: a capture-recapture study using national registers#398558Figshare
• Initial Development of a Brief Mind-Body Sexual Well-Being Program for Female Colorectal and Anal Cancer Survivors: A Two-Phase Study of Survivor Needs and Treatment Preferences.#399588NCBI PubMed Central
• Structure-Based Discovery of JN210 as a Potent Dual DCN1/HDAC Inhibitor for the Treatment of Nonsmall Cell Lung Cancer#417849Figshare
• Structure-Based Discovery of JN210 as a Potent Dual DCN1/HDAC Inhibitor for the Treatment of Nonsmall Cell Lung Cancer#417850Figshare
• Structure-Based Discovery of JN210 as a Potent Dual DCN1/HDAC Inhibitor for the Treatment of Nonsmall Cell Lung Cancer#417851Figshare
• Structure-Based Discovery of JN210 as a Potent Dual DCN1/HDAC Inhibitor for the Treatment of Nonsmall Cell Lung Cancer#417852Figshare
• Factors Associated With the Use of the Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology (LETSGO) mHealth App in Routine Follow-Up After Gynecologic Cancer Treatment: Observational Study.#420879NCBI PubMed Central
• Detecting effects of yoga therapy on heart rate variability and autonomic nervous system functioning in adults after cancer treatment: results from a study using single-subject experimental methods.#472280NCBI PubMed Central
• Multi-modal Imaging Analysis and Automatic Segmentation for Predicting Pathological Complete Response (pCR) in Breast Cancer#643285HAL (France)
• Cost-effectiveness of zanubrutinib versus ibrutinib as first-line treatment for patients with Waldenström macroglobulinemia in China#684722Figshare
• Tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the Asian subgroup of the RATIONALE-305 study#431806S-Space: Seoul National University
• The Efficacy and Safety of Iparomlimab/Tuvonralimab (Anti PD-1/CTLA-4) Combined With Albumin-bound Paclitaxel in Second-line Treatment of Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma#127566ClinicalTrials.gov
• Nurse-delivered brief behavioral treatment for insomnia in cancer survivors: a randomized controlled trial#156461Springer Nature OA
• The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer#226258ClinicalTrials.gov
• A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel#314318ClinicalTrials.gov
• Implementation and evaluation of an ambulatory care pathway for intra-arterial treatment of primary liver cancer: study protocol for a multicentre randomised controlled hybrid type 1 trial (CHOC).#439038NCBI PubMed Central
• Comparative efficacy of non-pharmacological interventions for individuals with cannabis use disorder: a systematic review and network meta-analysis protocol#477079PLOS
• “Like a Clinical Nurse Consultant in Your Pocket”—Parents’ and Health Care Providers’ Perceptions of a Co-Designed Smartphone App Following Treatment for Pediatric Cancer: Mixed Methods Evaluation Study.#671297NCBI PubMed Central
• Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer#481753ClinicalTrials.gov
• Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer#804796ClinicalTrials.gov
• Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer#256863ClinicalTrials.gov
• Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine#261491ClinicalTrials.gov
• A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers#261495ClinicalTrials.gov
• Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial)#326136HAL (France)
• Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy#387139ClinicalTrials.gov
• Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced Colorectal Carcinoma#804221ClinicalTrials.gov
• Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors#121363ClinicalTrials.gov
• Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer#146462ClinicalTrials.gov
• Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial#262149HAL (France)
• Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study#162479ClinicalTrials.gov
• Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer#256890ClinicalTrials.gov
• Dual-ligand-modified cantharidin nanoparticles for the treatment of hepatocellular carcinoma via the inhibition of Ephb4#261766Figshare
• Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC#307453ClinicalTrials.gov
• Adonertinib (FHND9041) versus Afatinib as First-line Treatment for Advanced Non-small-cell Lung Cancer with EGFR Sensitive Mutation (FHND9041-Ⅲ-01): A Multi-centre, Open-label, Randomised Phase 3 Trial#414785Europe PMC